Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyAl B. Benson, Lisa A. Gurski, Alan P. Venook et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 846
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in OncologyAl B. Benson, Frankie Jones, Alan P. Venook et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 333
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024Al B. Benson, Lisa A. Gurski, Alan P. Venook et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 244
Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyAl B. Benson, Katie Stehman, Alan P. Venook et al.|Journal of the National Comprehensive Cancer Network|2023Cited by 106
Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.Manuel Hidalgo, Daniel D. Von Hoff, Ron Epelbaum et al.|Journal of Clinical Oncology|2018Cited by 6